Exagen Reports Q1 2026 Earnings with Revenue Growth and Operational Improvements
Exagen (XGN) reported first-quarter revenue of $17.3 million, a 12% year-over-year increase driven by strong test volume growth and higher average selling prices. The company also improved its adjusted EBITDA loss to -$2.2 million, showing progress compared to the prior year.
Tickers: $XGN
Topics: adjusted_ebitda asp_growth operating_expenses revenue test_volume_growth